IPhone / Mobile Compatible

Viewport Meta

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

HSTS

WordPress

Global Site Tag

nginx

Chief Business Officer

Bethany Mancilla

Founder, Chief Technology Officer

Nick Goeden, PhD

Chief Operating Officer

Rayne Waller

Chief Executive Officer

Robert Cuddihy

Co-Founder and Board of Directors Member

Viviana Gradinaru

Vice President Clinical Development

Heather Cahan

Vice President Technical Operations

Rob Murphy

Director Preclinical Research

Allison Knoll

Executive Director of Manufacturing

Carrie Pedeferri

Director

David Chu

Clare Ozawa

Susan Catalano

Chief Scientific Officer

Chief Manufacturing and Quality Officer

Nick Goeden

Co-Founder and Chief Technology Officer

Nicholas Flytzanis

Founder, Chief Research and Innovation Officer

University of Southern California Alumni Founded Companies

Greater Los Angeles Area Companies With Less Than $10M in Revenue (Top 10K)

West Coast Companies With Fewer Than 100 Employees (Top 10K)

Companies With Less Than $1B in Revenue (Top 10K)

Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders. It features a proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the diseased organ.

AbbVie

Corporate Round - Capsida

Versant Ventures

Westlake Village BioPartners

Series A - Capsida

Newbury Park

California

United States

North America

Capsida

Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene ...

Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing ...

Capsida Biotherapeutics Presents Preclinical Data for Parkinson's Disease

Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration

Capsida Biotherapeutics Presents Preclinical Data for Parkinson’s Disease

Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations

Philippines

Asia

Bangladesh

India

Capsida owns Capsida Thousand Oaks

Capsida owns Capsida Los Angeles

Capsida Biotherapeutics is a fully integrated next-generation gene therapy platform company that originated from groundbreaking research at Caltech. The company focuses on capsid engineering, cargo optimization, translational biology, process development and manufacturing, and clinical development, with the goal of creating customized therapies for both rare and common diseases across all ages.

Capsida Biotherapeutics

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 10:57 AM	30750dd0
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 10:57 AM	24bae039
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	1d6bd829
crunchbase profile	general	Nov 4, 2024 11:14 AM	9d318d6a
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	41e674d2
peers	general
news basic	general	Mar 8, 2024 10:57 AM	2c8b9581
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CAPS

COM:CAPSIDA

Capsida Biotherapeutics